# A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

> **NCT04544449** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 985 (actual)

## Conditions studied

- Multiple Sclerosis, Primary Progressive

## Interventions

- **DRUG:** Fenebrutinib
- **DRUG:** Ocrelizumab
- **DRUG:** Placebo matched to ocrelizumab
- **DRUG:** Placebo matched to fenebrutinib

## Key facts

- **NCT ID:** NCT04544449
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-26
- **Primary completion:** 2025-09-17
- **Final completion:** 2027-07-21
- **Target enrollment:** 985 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544449, "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04544449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*